Welcome to our dedicated page for Vir Biotechnology SEC filings (Ticker: VIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vir Biotechnology, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company with common stock traded under VIR. Its SEC disclosures cover operating and financial results, cash and investment updates, clinical and regulatory communications, material agreements, and capital-structure actions related to common stock issuances and collaborations.
The company’s proxy and current reports also describe board and executive governance, compensation matters, shareholder voting items, leadership changes, and registered security information. For Vir’s business model, the filings connect pipeline spending, development-stage risk factors, collaboration economics, intellectual property matters, and financing activity to programs in chronic hepatitis delta, PRO-XTEN® T-cell engagers, and preclinical infectious disease and oncology research.
VIR notice reports a proposed sale of 1,829 shares of common stock tied to restricted stock vesting on 02/23/2026.
The filing also records that Brent Sabatini disposed of 1,530 shares on 02/13/2026, with the broker listed as Fidelity Brokerage Services LLC.
Vir Biotechnology, Inc. executive Brent Sabatini, the SVP and Chief Accounting Officer, reported an automatic sale of 1,530 shares of common stock. The shares were sold in an open-market transaction at $7.79 per share to satisfy tax withholding obligations tied to vesting restricted stock units, under a Rule 10b5-1 arrangement.
The filing notes this was a mandatory, non-discretionary sale rather than a voluntary trade by Sabatini. After the transaction, he directly owned 47,872 shares of Vir Biotechnology common stock, reflecting his continuing equity stake in the company.
Vir Biotechnology, Inc. received an updated ownership filing from SoftBank-affiliated entities. SB Investment Advisers (UK) Limited, SoftBank Vision Fund (AIV M1) L.P., and SVF Endurance (Cayman) Limited report beneficial ownership of 13,116,977 shares of Vir common stock.
These shares represent 9.4% of Vir’s outstanding common stock, based on 139,125,032 shares outstanding as of October 29, 2025. SVF Endurance (Cayman) Limited is the record holder of the shares, SVF is its sole owner, and SB Investment Advisers (UK) Limited manages SVF and controls investment and voting decisions, so each entity may be deemed to share beneficial ownership.
Vir Biotechnology received a notice of proposed stock sales under Rule 144. The filing covers planned sales of 1,530 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of 11,918.09 and listing on NASDAQ.
The shares were acquired on 02/13/2026 through restricted stock vesting from the issuer as compensation, with payment also dated 02/13/2026. The notice states that the person for whose account the securities are to be sold does not know of any undisclosed material adverse information about Vir’s operations.
Vir Biotechnology director Vicki L. Sato reported a pre-planned stock sale. On 02/02/2026, she sold 22,000 shares of Vir Biotechnology common stock at a weighted average price of $7.7123 per share under a Rule 10b5-1 trading plan adopted on March 27, 2025.
After this transaction, she beneficially owns 1,144,391 shares directly. A Rule 10b5-1 plan allows insiders to schedule trades in advance, helping separate routine portfolio moves from trading based on nonpublic information.
SVF Endurance (Cayman) Limited has filed a notice to sell 1,251,303 shares of VIR common stock through broker BTIG, LLC, with an approximate sale date of 01/14/2026 on NASDAQ. The filing lists an aggregate market value of $8533886.46 for these shares and notes that 139,125,032 shares of the issuer’s common stock are outstanding.
The seller’s shares were acquired on 10/16/2019 upon automatic conversion of convertible preferred stock that was fully paid for in multiple cash transactions completed by 01/31/2019. Over the past three months, the same holder has sold multiple blocks of common stock, including 220,535 shares on 10/20/2025 and 297,495 shares on 12/04/2025, with disclosed gross proceeds for each transaction.
Vir Biotechnology, Inc. reported that it has issued a press release providing a preliminary estimate of its cash, cash equivalents and investments balance as of December 31, 2025. This figure is unaudited and may change, and the company plans to report its full fourth quarter and full-year 2025 financial results in late February 2026.
The company also plans to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 at 3:45 p.m. PT. The related slide deck is being made available as an exhibit and on the company’s investor website, which will also host a live webcast and a 30-day archive of the presentation.
Vir Biotechnology director Vicki L. Sato sold 22,000 shares of common stock on January 2, 2026 at a weighted average price of $5.9265 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2025.
Following this transaction, Sato beneficially owned 1,166,391 shares of Vir Biotechnology common stock, held in direct ownership.
Vir Biotechnology, Inc. entered a license agreement with Norgine Pharma UK Limited for commercial rights to its tobevibart and elebsiran combination for chronic hepatitis delta in Europe, Australia and New Zealand. Vir will receive an initial EUR 55 million reimbursement of development costs and is eligible for up to EUR 495 million in clinical, regulatory and sales milestones, plus tiered mid-teen to high-twenties percent royalties on net sales, while Norgine will contribute about 25% of go-forward external costs for Vir’s ECLIPSE registrational program.
Vir retained rights to the combination in the United States and most other markets outside the Greater China Territory. The company also highlighted Phase 2 SOLSTICE data in chronic hepatitis delta, where 66% (21/32) of participants on the monthly combination achieved sustained HDV RNA target not detected at Week 48, about 90% (29/32) reached hepatitis B surface antigen levels below 10 IU/mL, and 56% (18/32) achieved ALT normalization by Week 48, with the regimen reported as well-tolerated and no grade 3 or higher treatment-related adverse events or treatment-related discontinuations.